The biggest dilemma in my life when a third-party app asks me how I want to use their services – through my Google (GOOGL) account or Facebook (FB). Often, the best option seems to be switching off the computer!
Up till last year, Google (GOOGL) used to monitor e-mails sent by its users to provide personalized advertisements. However, following public outcry over data privacy, the tech giant stopped this practice in 2017. But the latest report by Wall Street Journal suggests that your e-mails are still not private. According to the report, Google continues to allow developers of various third-party apps to access mails sent on its Gmail platform.
The report says, “Email data collectors use software to scan millions of messages a day, looking for clues about consumers that they can sell to marketers, hedge funds, and other businesses.” Though Google has stated that the company vets the developers who have access to private e-mails, this is hardly assuring in a privacy-crisis environment.
RELATED: Soon, Facebook ads to come under user scrutiny
Meanwhile, the tech giant also said the company allows its own employees to go through private e-mails in specific cases involving bugs, or a probe into user abuse.
Gmail is the largest e-mail provider with about 1.4 billion users across the globe. The WSJ article states that employees of data solutions company Return Path Inc used as many as 8,000 user mails just to train the software of the company.
RELATED: Google’s internal message boards are not ‘free-for-all’ anymore
The developments happen when major technology companies are facing a backlash over not being able to manage the massive amounts of data it receives every day. Rival Facebook has recently been chastised for its back-to-back data breaches. Both Facebook and Google are also potentially facing massive fines in the UK under the newly launched General Data Protection Regulation (GDPR) law.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on